Why the study?
Does EGIS-7229 alter myocardial refractoriness and ventricular fibrillation threshold compared to pure I(Kr) blockers in preclinical models?
Does EGIS-7229 alter myocardial refractoriness and ventricular fibrillation threshold compared to pure I(Kr) blockers in preclinical models?
EGIS-7229 increases myocardial refractoriness with less reverse frequency dependence than pure I(Kr) blockers, suggesting strong antiarrhythmic potential with lower risk of early afterdepolarizations.
No takes yet. Share an insight, caveat, or question.
Supports exploration of agents with reduced reverse frequency dependence; leaves open clinical translation from animal models.
Kovács et al. (2001) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: